| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Celiac Disease | 51 | 2024 | 229 | 11.410 |
Why?
|
| Probiotics | 18 | 2024 | 99 | 4.020 |
Why?
|
| Glutens | 21 | 2024 | 88 | 3.940 |
Why?
|
| Diet, Gluten-Free | 17 | 2022 | 64 | 2.550 |
Why?
|
| Diarrhea | 9 | 2020 | 180 | 2.170 |
Why?
|
| Gastrointestinal Diseases | 8 | 2017 | 156 | 1.360 |
Why?
|
| Food Hypersensitivity | 5 | 2018 | 90 | 1.290 |
Why?
|
| Transglutaminases | 9 | 2023 | 44 | 1.280 |
Why?
|
| Child | 35 | 2023 | 7750 | 1.210 |
Why?
|
| Immunoglobulin A | 5 | 2023 | 94 | 1.210 |
Why?
|
| Irritable Bowel Syndrome | 5 | 2020 | 46 | 1.060 |
Why?
|
| Autoantibodies | 8 | 2019 | 286 | 1.020 |
Why?
|
| Triticum | 3 | 2017 | 24 | 0.980 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2023 | 686 | 0.910 |
Why?
|
| Child, Preschool | 17 | 2020 | 4042 | 0.770 |
Why?
|
| Dysbiosis | 1 | 2024 | 103 | 0.760 |
Why?
|
| Colitis, Ulcerative | 3 | 2024 | 843 | 0.750 |
Why?
|
| Gastroenteritis | 2 | 2015 | 26 | 0.730 |
Why?
|
| Humans | 81 | 2024 | 98370 | 0.720 |
Why?
|
| HLA-DQ Antigens | 4 | 2019 | 52 | 0.710 |
Why?
|
| Duodenum | 5 | 2022 | 113 | 0.700 |
Why?
|
| Gastroenterology | 6 | 2019 | 162 | 0.680 |
Why?
|
| Abdominal Pain | 3 | 2020 | 149 | 0.670 |
Why?
|
| Oryza | 2 | 2018 | 49 | 0.650 |
Why?
|
| Constipation | 2 | 2020 | 69 | 0.650 |
Why?
|
| Infant | 17 | 2020 | 3361 | 0.640 |
Why?
|
| Practice Guidelines as Topic | 7 | 2019 | 1116 | 0.640 |
Why?
|
| Biopsy | 9 | 2023 | 1225 | 0.620 |
Why?
|
| Adolescent | 20 | 2020 | 10140 | 0.600 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2024 | 661 | 0.600 |
Why?
|
| Blood Chemical Analysis | 1 | 2019 | 40 | 0.600 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 373 | 0.590 |
Why?
|
| Weaning | 4 | 2016 | 26 | 0.580 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2019 | 22 | 0.580 |
Why?
|
| Crohn Disease | 6 | 2024 | 859 | 0.570 |
Why?
|
| Automation | 1 | 2019 | 118 | 0.570 |
Why?
|
| Gliadin | 3 | 2016 | 17 | 0.550 |
Why?
|
| Intestinal Mucosa | 11 | 2024 | 845 | 0.550 |
Why?
|
| Wheat Hypersensitivity | 2 | 2017 | 4 | 0.550 |
Why?
|
| Inflammatory Bowel Diseases | 5 | 2024 | 684 | 0.530 |
Why?
|
| Egg Yolk | 1 | 2017 | 4 | 0.520 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 1570 | 0.520 |
Why?
|
| Enterocolitis, Necrotizing | 4 | 2015 | 86 | 0.510 |
Why?
|
| Beer | 1 | 2016 | 1 | 0.500 |
Why?
|
| Direct Service Costs | 1 | 2016 | 2 | 0.490 |
Why?
|
| Infant Nutritional Physiological Phenomena | 2 | 2007 | 21 | 0.480 |
Why?
|
| Health Status | 2 | 2011 | 388 | 0.460 |
Why?
|
| Lactobacillus | 5 | 2011 | 26 | 0.460 |
Why?
|
| Diet, Mediterranean | 1 | 2015 | 6 | 0.440 |
Why?
|
| Breast Feeding | 5 | 2016 | 113 | 0.440 |
Why?
|
| Ambulatory Care | 1 | 2016 | 202 | 0.430 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 480 | 0.430 |
Why?
|
| Treatment Outcome | 14 | 2024 | 9770 | 0.420 |
Why?
|
| Autoimmunity | 3 | 2010 | 195 | 0.370 |
Why?
|
| Infant, Newborn | 8 | 2020 | 2551 | 0.370 |
Why?
|
| Diet | 3 | 2017 | 469 | 0.370 |
Why?
|
| GTP-Binding Proteins | 4 | 2020 | 150 | 0.360 |
Why?
|
| Hospitalization | 2 | 2016 | 988 | 0.350 |
Why?
|
| Health Care Surveys | 1 | 2012 | 282 | 0.330 |
Why?
|
| Food | 1 | 2011 | 93 | 0.330 |
Why?
|
| Fetal Development | 1 | 2011 | 37 | 0.320 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2015 | 321 | 0.320 |
Why?
|
| Guideline Adherence | 1 | 2012 | 250 | 0.310 |
Why?
|
| Remission Induction | 4 | 2018 | 764 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2015 | 992 | 0.300 |
Why?
|
| Intestine, Small | 4 | 2016 | 321 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2019 | 2579 | 0.290 |
Why?
|
| Child Development | 1 | 2011 | 179 | 0.280 |
Why?
|
| Child Nutrition Sciences | 2 | 2018 | 2 | 0.280 |
Why?
|
| Rotavirus Infections | 1 | 2008 | 10 | 0.270 |
Why?
|
| Male | 24 | 2022 | 47263 | 0.270 |
Why?
|
| Colon | 3 | 2011 | 565 | 0.270 |
Why?
|
| Adult | 16 | 2019 | 29587 | 0.270 |
Why?
|
| Immunologic Factors | 1 | 2008 | 180 | 0.250 |
Why?
|
| Female | 22 | 2020 | 51761 | 0.250 |
Why?
|
| Cross Infection | 4 | 2011 | 155 | 0.250 |
Why?
|
| Societies, Medical | 4 | 2018 | 687 | 0.240 |
Why?
|
| Milk, Human | 1 | 2007 | 54 | 0.240 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2018 | 171 | 0.240 |
Why?
|
| Colonic Diseases | 1 | 2016 | 60 | 0.240 |
Why?
|
| Bifidobacterium | 3 | 2011 | 21 | 0.240 |
Why?
|
| Inflammation | 3 | 2019 | 1133 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 4 | 2015 | 880 | 0.230 |
Why?
|
| Health Care Reform | 1 | 2016 | 78 | 0.230 |
Why?
|
| Infant Formula | 1 | 2005 | 20 | 0.230 |
Why?
|
| Risk Factors | 10 | 2018 | 6273 | 0.220 |
Why?
|
| Respiratory Tract Infections | 1 | 2006 | 112 | 0.220 |
Why?
|
| Retrospective Studies | 8 | 2020 | 11043 | 0.220 |
Why?
|
| Colectomy | 1 | 2016 | 203 | 0.220 |
Why?
|
| Environmental Exposure | 1 | 2008 | 405 | 0.220 |
Why?
|
| Physicians | 1 | 2012 | 685 | 0.210 |
Why?
|
| Antibodies | 2 | 2019 | 349 | 0.210 |
Why?
|
| Double-Blind Method | 4 | 2018 | 1790 | 0.210 |
Why?
|
| Interleukin-15 | 3 | 2015 | 78 | 0.210 |
Why?
|
| Saccharomyces | 2 | 2015 | 22 | 0.200 |
Why?
|
| Cross-Over Studies | 2 | 2018 | 394 | 0.200 |
Why?
|
| Women's Health | 1 | 2005 | 120 | 0.200 |
Why?
|
| Pediatrics | 2 | 2018 | 421 | 0.190 |
Why?
|
| Evidence-Based Medicine | 4 | 2016 | 481 | 0.190 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 286 | 0.190 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 1785 | 0.190 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 2 | 2015 | 35 | 0.190 |
Why?
|
| Acute Disease | 4 | 2008 | 860 | 0.180 |
Why?
|
| Disulfides | 1 | 2022 | 66 | 0.180 |
Why?
|
| Thiorphan | 1 | 2002 | 5 | 0.180 |
Why?
|
| Genetic Testing | 2 | 2019 | 606 | 0.180 |
Why?
|
| Animals | 10 | 2024 | 28981 | 0.180 |
Why?
|
| Comorbidity | 2 | 2016 | 1035 | 0.170 |
Why?
|
| Meta-Analysis as Topic | 2 | 2015 | 86 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 2017 | 0.170 |
Why?
|
| Cohort Studies | 2 | 2019 | 3228 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 663 | 0.160 |
Why?
|
| Intestines | 3 | 2019 | 442 | 0.160 |
Why?
|
| Insurance, Health | 2 | 2016 | 187 | 0.160 |
Why?
|
| Environment | 2 | 2014 | 233 | 0.160 |
Why?
|
| Child Day Care Centers | 2 | 2011 | 8 | 0.160 |
Why?
|
| Time Factors | 5 | 2018 | 5577 | 0.160 |
Why?
|
| Aging | 1 | 2005 | 770 | 0.160 |
Why?
|
| Laxatives | 1 | 2020 | 14 | 0.160 |
Why?
|
| Health Care Costs | 2 | 2016 | 259 | 0.160 |
Why?
|
| Antigens | 2 | 2019 | 225 | 0.150 |
Why?
|
| Quality of Life | 3 | 2016 | 1899 | 0.150 |
Why?
|
| Th1 Cells | 2 | 2017 | 173 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2016 | 2599 | 0.140 |
Why?
|
| Starch | 1 | 2018 | 9 | 0.140 |
Why?
|
| Body Mass Index | 2 | 2020 | 867 | 0.140 |
Why?
|
| Age Factors | 2 | 2018 | 1974 | 0.140 |
Why?
|
| Pathology, Clinical | 1 | 2018 | 39 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2019 | 119 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 383 | 0.130 |
Why?
|
| Prevalence | 3 | 2020 | 1393 | 0.130 |
Why?
|
| Reoviridae Infections | 1 | 2017 | 7 | 0.130 |
Why?
|
| Europe | 3 | 2018 | 357 | 0.130 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 122 | 0.130 |
Why?
|
| Case-Control Studies | 3 | 2016 | 2009 | 0.130 |
Why?
|
| Prognosis | 3 | 2016 | 4126 | 0.130 |
Why?
|
| Flour | 1 | 2016 | 4 | 0.130 |
Why?
|
| Sorghum | 1 | 2016 | 5 | 0.130 |
Why?
|
| Hordeum | 1 | 2016 | 10 | 0.130 |
Why?
|
| Feeding Behavior | 2 | 2020 | 352 | 0.130 |
Why?
|
| Internationality | 1 | 2016 | 80 | 0.120 |
Why?
|
| Young Adult | 3 | 2019 | 7568 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2016 | 178 | 0.120 |
Why?
|
| Middle Aged | 7 | 2019 | 29532 | 0.120 |
Why?
|
| Age Distribution | 1 | 2016 | 212 | 0.120 |
Why?
|
| Antibody Formation | 1 | 2016 | 173 | 0.120 |
Why?
|
| Allergens | 1 | 2017 | 196 | 0.120 |
Why?
|
| Leadership | 1 | 2018 | 160 | 0.120 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 155 | 0.120 |
Why?
|
| Peptides | 1 | 2019 | 671 | 0.120 |
Why?
|
| Infant, Premature | 2 | 2015 | 307 | 0.110 |
Why?
|
| Reference Values | 1 | 2016 | 608 | 0.110 |
Why?
|
| Leukotrienes | 1 | 2015 | 20 | 0.110 |
Why?
|
| Immunoglobulin E | 2 | 2017 | 156 | 0.110 |
Why?
|
| Attitude | 1 | 2016 | 133 | 0.110 |
Why?
|
| Adolescent Health | 1 | 2014 | 6 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2019 | 1100 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 2056 | 0.110 |
Why?
|
| Cysteine | 1 | 2015 | 150 | 0.110 |
Why?
|
| Cell Communication | 1 | 2015 | 223 | 0.100 |
Why?
|
| Dietary Supplements | 2 | 2016 | 152 | 0.100 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 194 | 0.100 |
Why?
|
| Mentors | 1 | 2014 | 103 | 0.100 |
Why?
|
| Epithelial Cells | 2 | 2015 | 710 | 0.100 |
Why?
|
| Global Health | 1 | 2015 | 215 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2015 | 257 | 0.090 |
Why?
|
| United States | 5 | 2016 | 8262 | 0.090 |
Why?
|
| Feces | 2 | 2011 | 390 | 0.090 |
Why?
|
| Faculty, Medical | 1 | 2014 | 194 | 0.090 |
Why?
|
| Endoscopy, Digestive System | 1 | 2012 | 76 | 0.090 |
Why?
|
| History, 21st Century | 3 | 2018 | 196 | 0.090 |
Why?
|
| Fluid Therapy | 2 | 2002 | 68 | 0.090 |
Why?
|
| History, 20th Century | 3 | 2018 | 323 | 0.090 |
Why?
|
| Community-Acquired Infections | 1 | 2011 | 66 | 0.080 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2011 | 8 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 3032 | 0.080 |
Why?
|
| Tight Junctions | 1 | 2011 | 158 | 0.080 |
Why?
|
| Mass Screening | 2 | 2014 | 751 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2019 | 4818 | 0.080 |
Why?
|
| Incidence | 1 | 2015 | 1787 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2010 | 127 | 0.080 |
Why?
|
| Infant, Premature, Diseases | 1 | 2010 | 84 | 0.080 |
Why?
|
| Disease Management | 1 | 2012 | 377 | 0.070 |
Why?
|
| Phospholipases A2, Cytosolic | 1 | 2009 | 4 | 0.070 |
Why?
|
| Family | 1 | 2010 | 329 | 0.070 |
Why?
|
| Diet Therapy | 1 | 2008 | 19 | 0.070 |
Why?
|
| Italy | 2 | 2020 | 113 | 0.070 |
Why?
|
| Biological Products | 1 | 2010 | 190 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 2577 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 2022 | 304 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2008 | 174 | 0.060 |
Why?
|
| Infant Food | 1 | 2007 | 11 | 0.060 |
Why?
|
| Massachusetts | 1 | 2016 | 38 | 0.060 |
Why?
|
| Immune System | 1 | 2008 | 106 | 0.060 |
Why?
|
| Dysentery | 1 | 2006 | 3 | 0.060 |
Why?
|
| Helicobacter Infections | 1 | 2006 | 36 | 0.060 |
Why?
|
| Helicobacter pylori | 1 | 2006 | 36 | 0.060 |
Why?
|
| Nutritional Requirements | 1 | 2005 | 17 | 0.060 |
Why?
|
| Consumer Product Safety | 1 | 2005 | 12 | 0.060 |
Why?
|
| Pyloric Stenosis | 1 | 2005 | 7 | 0.060 |
Why?
|
| Serologic Tests | 2 | 2005 | 42 | 0.060 |
Why?
|
| Professional-Patient Relations | 1 | 2005 | 48 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 297 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2010 | 1006 | 0.050 |
Why?
|
| Biomarkers | 2 | 2022 | 2021 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 667 | 0.050 |
Why?
|
| Developmental Disabilities | 1 | 2005 | 217 | 0.050 |
Why?
|
| School Nursing | 1 | 2003 | 4 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2015 | 3633 | 0.050 |
Why?
|
| Pregnancy | 1 | 2011 | 3269 | 0.050 |
Why?
|
| Obesity | 2 | 2020 | 1077 | 0.050 |
Why?
|
| Sulfhydryl Compounds | 1 | 2022 | 67 | 0.040 |
Why?
|
| Diarrhea, Infantile | 1 | 2002 | 2 | 0.040 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2002 | 12 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2019 | 453 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 195 | 0.040 |
Why?
|
| Antidiarrheals | 1 | 2002 | 14 | 0.040 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2001 | 2 | 0.040 |
Why?
|
| Developed Countries | 1 | 2002 | 25 | 0.040 |
Why?
|
| Rats | 2 | 2022 | 4074 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2002 | 71 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2008 | 826 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2002 | 93 | 0.040 |
Why?
|
| Developing Countries | 1 | 2002 | 101 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2019 | 988 | 0.040 |
Why?
|
| Aged | 3 | 2017 | 21844 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2020 | 84 | 0.040 |
Why?
|
| Thinness | 1 | 2020 | 49 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 4044 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2006 | 1791 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2015 | 743 | 0.040 |
Why?
|
| Homeostasis | 1 | 2022 | 474 | 0.040 |
Why?
|
| Starvation | 1 | 1999 | 21 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2002 | 970 | 0.040 |
Why?
|
| Bacterial Adhesion | 1 | 1999 | 84 | 0.040 |
Why?
|
| Cecum | 1 | 1999 | 78 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2006 | 1647 | 0.040 |
Why?
|
| Intestinal Absorption | 1 | 2019 | 125 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2022 | 489 | 0.040 |
Why?
|
| Overweight | 1 | 2020 | 128 | 0.040 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2019 | 19 | 0.040 |
Why?
|
| Butyrophilins | 1 | 2019 | 28 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 456 | 0.040 |
Why?
|
| Anniversaries and Special Events | 1 | 2018 | 16 | 0.030 |
Why?
|
| North America | 1 | 2018 | 210 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 123 | 0.030 |
Why?
|
| Reoviridae | 1 | 2017 | 6 | 0.030 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2017 | 18 | 0.030 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2017 | 23 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2016 | 149 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2017 | 102 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2019 | 719 | 0.030 |
Why?
|
| Atrophy | 1 | 2016 | 131 | 0.030 |
Why?
|
| Child Health Services | 1 | 2016 | 36 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2018 | 245 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 442 | 0.030 |
Why?
|
| Receptors, Leukotriene | 1 | 2015 | 10 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2015 | 23 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2017 | 170 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 62 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2015 | 32 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1519 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2009 | 1145 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 125 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 119 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2015 | 178 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2017 | 386 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 1607 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2014 | 141 | 0.020 |
Why?
|
| Algorithms | 1 | 2001 | 2003 | 0.020 |
Why?
|
| Intestinal Neoplasms | 1 | 2014 | 77 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 513 | 0.020 |
Why?
|
| Recurrence | 2 | 2005 | 1264 | 0.020 |
Why?
|
| Guanidines | 1 | 2011 | 34 | 0.020 |
Why?
|
| Enema | 1 | 2011 | 37 | 0.020 |
Why?
|
| Defecation | 1 | 2011 | 26 | 0.020 |
Why?
|
| Occludin | 1 | 2011 | 66 | 0.020 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2011 | 70 | 0.020 |
Why?
|
| Permeability | 1 | 2011 | 145 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 261 | 0.020 |
Why?
|
| Biological Transport | 1 | 2011 | 402 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2010 | 39 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2011 | 264 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2858 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2011 | 286 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3616 | 0.020 |
Why?
|
| Pain Management | 1 | 2011 | 194 | 0.020 |
Why?
|
| Cell Degranulation | 1 | 2009 | 14 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1615 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2009 | 63 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2009 | 98 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2009 | 86 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2009 | 125 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2009 | 218 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 2667 | 0.020 |
Why?
|
| Pouchitis | 1 | 2008 | 58 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 679 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2006 | 18 | 0.020 |
Why?
|
| Mice | 2 | 2017 | 12735 | 0.010 |
Why?
|
| Vaginosis, Bacterial | 1 | 2006 | 8 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 7418 | 0.010 |
Why?
|
| Bacteria | 1 | 2010 | 546 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 143 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 116 | 0.010 |
Why?
|
| Placebos | 1 | 2005 | 210 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2011 | 1290 | 0.010 |
Why?
|
| Lymphoma | 1 | 2006 | 255 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 479 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 403 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 2224 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 2897 | 0.010 |
Why?
|
| HLA Antigens | 1 | 2003 | 238 | 0.010 |
Why?
|
| Haplotypes | 1 | 2003 | 657 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 1568 | 0.010 |
Why?
|
| Ion Transport | 1 | 1999 | 87 | 0.010 |
Why?
|
| Logistic Models | 1 | 2003 | 1276 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1999 | 385 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 822 | 0.010 |
Why?
|
| Hepatectomy | 1 | 1999 | 202 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 2023 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1999 | 1110 | 0.010 |
Why?
|